ID   AE1-2a
AC   CVCL_U656
SY   AE1-2A
DR   cancercelllines; CVCL_U656
DR   Wikidata; Q54608893
RX   PubMed=8648763;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 11
//
RX   PubMed=8648763; DOI=10.1128/JVI.70.6.4173-4178.1996;
RA   Gorziglia M.I., Kadan M.J., Yei S., Lim J., Lee G.M., Luthra R.,
RA   Trapnell B.C.;
RT   "Elimination of both E1 and E2 from adenovirus vectors further
RT   improves prospects for in vivo human gene therapy.";
RL   J. Virol. 70:4173-4178(1996).
//